FDA Biotech Consultants Should Be Vetted By Companies, BIO Says

The Biotechnology Industry Organization is asking FDA to allow sponsors to review the agency's choice of outside consultants as part of its clinical protocol evaluation program

More from Archive

More from Pink Sheet